This phase II trial is trying to determine the clinical benefit of using two types of immunotherapy (nivolumab combined with ipilimumab) to treat neuroendocrine cancers, biliary tract cancers, gynaecological cancers and MSI-H cancers (excluding colorectal cancer).
This trial is treating multiple types of cancer including neuroendocrine cancers, biliary tract cancers, gynaecological cancers and MSI-H cancers (excluding colorectal cancer).
This is a systemic therapy trial.
You may be excluded from this trial if:
- You have a certain disease or psychological condition.
- You have been diagnosed with a prior or secondary type of cancer.
- You have had certain treatments, surgical procedures or drugs.
Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.
Clinical Summary Read More
Trial Identifiers
Use the hyperlinks, where available to access additional clinical trial information.
Scientific Title
Ipilimumab and Nivolumab Combination Therapy in Patients With Selected Immunotherapy Sensitive Advanced Rare Cancers
Commercial Sponsor
dlai Nortye Biopharma Co., Ltd
Summary
Eligible participants will be treated with Nivolumab (3 mg/kg) and ipilimumab (1 mg/kg) concurrently every 3 weeks for 4 doses, followed by nivolumab (480mg) only every 4 weeks until progression (up to 2 years).
Recruiting Hospitals Read More